HY-0010

HY-0010 is a small molecule dual-targeting inhibitor currently in the IND-enabling phase of development by Huiyu Anlaibo Pharmaceutical Technology, a subsidiary of Sichuan Huiyu Pharmaceutical. As a dual-targeting agent, HY-0010 is designed to simultaneously inhibit two distinct molecular pathways involved in the proliferation and survival of cancer cells. While the specific biological targets are not explicitly disclosed in the company's primary pipeline documentation, this class of inhibitors is typically developed to overcome resistance mechanisms and provide broader therapeutic coverage than single-target agents. The drug is being investigated for the treatment of various solid tumors and is expected to be administered orally. HY-0010 represents part of Huiyu's expanding portfolio of targeted small molecule oncology therapeutics.